ConductScience.org, home
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
API referenceFor AI assistants

Trial · NCT03484702

Participant flow42

How many started, completed or left each group, period by period.

1 to 20 of 42

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Pre-Treatment Period - LeukapheresisSTARTEDCohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy45
Pre-Treatment Period - LeukapheresisSTARTEDCohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy32
Pre-Treatment Period - LeukapheresisSTARTEDCohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 214
Pre-Treatment Period - LeukapheresisSTARTEDCohort 4: Newly Diagnosed High-Grade B-cell Lymphoma4
Pre-Treatment Period - LeukapheresisSTARTEDCohort 5: Primary Central Nervous System Lymphoma7
Pre-Treatment Period - LeukapheresisSTARTEDCohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting11
Pre-Treatment Period - LeukapheresisCOMPLETEDCohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy43
Pre-Treatment Period - LeukapheresisCOMPLETEDCohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy27
Pre-Treatment Period - LeukapheresisCOMPLETEDCohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 212
Pre-Treatment Period - LeukapheresisCOMPLETEDCohort 4: Newly Diagnosed High-Grade B-cell Lymphoma1
Pre-Treatment Period - LeukapheresisCOMPLETEDCohort 5: Primary Central Nervous System Lymphoma5
Pre-Treatment Period - LeukapheresisCOMPLETEDCohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting10
Pre-Treatment Period - LeukapheresisNOT COMPLETEDCohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy2
Pre-Treatment Period - LeukapheresisNOT COMPLETEDCohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy5
Pre-Treatment Period - LeukapheresisNOT COMPLETEDCohort 3: Japan Specific - Meeting Eligibility Criteria for Cohort 1 or 22
Pre-Treatment Period - LeukapheresisNOT COMPLETEDCohort 4: Newly Diagnosed High-Grade B-cell Lymphoma3
Pre-Treatment Period - LeukapheresisNOT COMPLETEDCohort 5: Primary Central Nervous System Lymphoma2
Pre-Treatment Period - LeukapheresisNOT COMPLETEDCohort 7: Meeting Cohort 1 Criteria Suitable for Treatment in an Outpatient Setting1
Treatment PeriodSTARTEDCohort 1: Diffuse B-cell Lymphoma Who Failed ≥ 2 Lines of Therapy43
Treatment PeriodSTARTEDCohort 2: Transplant Ineligible Diffuse B-cell Lymphoma Who Failed First Line Therapy27

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03484702/flow

API referenceFor AI assistants